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Abstract
Adrenocortical carcinoma is an uncommon malignancy and feminizing symptoms secondary to
adrenal estrogen-secretion are extremely rare. The direct secretion of estradiol by adrenocortical
tumors requires, in addition to the expression of aromatase (CYP19), the expression of one or more
of the reductive 17β-hydroxysteroid dehydrogenases. The expression of CYP19 transcripts and
protein were markedly induced in the H295 adrenocortical carcinoma cell line after treatment with
either forskolin or vasoactive intestinal peptide (VIP). Western immunoblotting demonstrated a
marked induction of the CYP19 protein of characteristic size after only a short (6 h) treatment period
with VIP or forskolin. The CYP19 mRNA transcripts were derived from both promoters PII (Ic) and
I.3 (Id) after treatment with both agents. The reductive type 5 17β-hydroxysteroid dehydrogenase
(AKR1C3) was also constitutively expressed in the H295 cells but neither its mRNA transcript nor
protein levels were altered after forskolin or VIP treatment. Western immunoblotting of an estrogen-
secreting adrenal carcinoma revealed notable levels of both aromatase and AKR1C3 expression while
an aldosterone-producing adrenal adenoma lacked aromatase expression and showed a reduced level
of AKR1C3 expression. Immunohistochemistry of the carcinoma-bearing adrenal revealed
localization of AKR1C3 not only in the tumor but also principally in the zona reticularis of the normal
adrenal tissue. Adrenal aromatase and AKR1C3 expression therefore appear to be features of
adrenocortical malignancies that are associated with biosynthesis of active estrogen.
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INTRODUCTION
Adrenocortical carcinoma is an uncommon malignancy with an incidence of 1-2 per million
population (Allolio and Fassnacht, 2006). Feminizing symptoms secondary to estrogen-
secretion are extremely rare (Gabrilove et al., 1965; Kimura et., 1995) and those arising in
cases of adrenocortical carcinomas were attributed to the peripheral aromatization of adrenal
androgens (Hemsell et al., 1977) as the aromatase enzyme is not usually considered a member
of the adrenocortical cytochrome P450 family. However, recent case reports have demonstrated
local aromatase cytochrome P450 (CYP19) mRNA and aromatase activity in such adrenal
tumors (Phornphutkul et al., 2001). The secretion of bioactive estrogen, specifically estradiol,
by adrenocortical tumors requires, in addition to the expression of aromatase, the expression
of one or more of the reductive 17β-hydroxysteroid dehydrogenases (17-ketosteroid
reductases). Candidate 17-ketosteroid reductases to be considered are types 1, 3, 5 and 12
17β-hydroxysteroid dehydrogenases.
The NCI-H295 cell line was originally derived from a human adrenocortical carcinoma that
expressed a multitude of steroidogenic cytochrome P450s including aromatase (Gazdar et al.,
1989). The cell lines derived from this carcinoma have become popular and standard models
for the study of human adrenocortical steroidogenesis (see Rainey et al., 1993; 1994; 2004).
Both NCI-H295A and NCI-H295R cells have been shown to express aromatase mRNA (Staels
et al., 1993) as well as enzyme activity (Watanabe and Nakajin, 2004; Watanabe et al.,
2006). The principal limitation to the utility of H295 cells as a primary model cell line for the
study of the underlying mechanisms involved in the diverse regulation of adrenocortical
steroidogenesis has been the apparent absence of functional ACTH receptors. This has required
many investigators to provoke the activation of the important PKA-cAMP signaling pathway
for steroidogenesis by the use of pharmacological interventions, e.g., addition of forskolin or
cAMP in its various forms. We were however able to demonstrate that vasoactive intestinal
peptide (VIP) acting via the VPAC1 receptors of H295 cells promoted increased cAMP and
subsequent a highly stimulated secretion of cortisol (Nicol et al., 2004). VIP was used as a
physiological peptide agent to evaluate aromatase expression in H295 cells because cAMP
signaling pathways have been shown to be important in aromatase expression in classical
steroidogenic tissues.
The expression of 17-ketosteroid reductases in the adrenal has also not been investigated in
depth, largely due to neither 17-hydroxy-C19-steroid nor estradiol secretion is commonly
associated with the human adrenal cortex. Therefore in the present study we describe our initial
studies to evaluate the putative pathway involving both aromatase and 17-ketosteroid reductase
in the biosynthesis of the active estrogen, estradiol, in H295 cells. We have also compared the
expression pattern of steroidogenic genes observed in H295 cells to the patterns observed in
two distinct adrenocortical tumors. The products of the first tumor were believed to promote
feminization (gynecomastia, loss of libido) in an adult male since these features were resolved
after a successful adrenalectomy. The second tumor was considered to be an aldosterone-
producing adrenal adenoma based on the clinical and biochemical history, and the post-
operative remission of hypertension and hypokalemia.
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MATERIALS AND METHODS
H295 cells
NCI-H295 cells were originally derived from a primary human adrenocortical carcinoma
removed at surgery from an adult female (Gazdar et al., 1990). The multipotent nature of the
cell line has been previously described and, in particular, the up-regulation of steroidogenic
gene expression promoted via cAMP-PKA and PKC intracellular signaling pathways (Staels
et., 1993, Rainey et al., 1994).
Cell culture
NCI-H295R cells (CRL-2128, ATCC, Rockville, MD, USA) were seeded into 12-well tissue
culture plates (5 × 105 cells per well) and maintained in Dulbecco’s modified Eagle’s medium/
F12 (DMEM/F12, Invitrogen, Paisley, Renfrew, UK) containing 2% Ultroser SF (Biosepra,
France), 5 μg/ml insulin, 5 μg/ml transferrin and 5 ng/ml sodium selenite (as 1% ITS,
Invitrogen) at 37°C with 5% CO2–95% air. For experiments, the cells were treated in the above
medium with the appropriate addition of vasointestinal peptide VIP (100 nM) or forskolin (10
μM) for 6 or 12 h (mRNA analysis) or 6-48 h (protein immunoblotting). After treatment, the
cells were washed with Hank’s balanced salt solution (HBSS, Invitrogen) and cell monolayers
harvested for either mRNA or protein analysis. Unless otherwise specified, all reagents were
obtained from Sigma, Poole, UK.
Subjects
Estrogen-producing adrenocortical carcinoma tissue was freshly obtained at adrenalectomy to
remove a right adrenal mass from a 54-year-old man who had presented with a short (2 month)
history of gynecomastia and loss of libido. Aldosterone-producing adrenal adenoma tissue was
obtained after laparoscopic surgery to remove a 2.6 cm left adrenal mass from a 53 year-old
woman who presented with a 10 year history of hypertension and hypokalemia. Endocrine
testing had conformed pre-operatively by 131I-norcholesterol scintigraphy. Written informed
consent was obtained from both patients pre-operatively to permit research studies to be
performed on the tissue removed at surgery.
Western immunoblotting
Tissue and cell extracts were prepared by sonication in 50mM Tris-HCl pH 7.6, 0.1% SDS,
1% deoxycholate (all from Sigma) containing a cocktail of proteinase inhibitors (Roche
Diagnostics Gmbh, Mannheim, Germany). After determination of protein concentration
(Bradford, 1976) tissue/cell protein was electrophoretically separated in a 10% SDS/PAGE gel
and transferred to a PVDF membrane (Millipore, Bedford, MA) followed by blocking in 5%
dried semi-skimmed milk diluted in PBST for 2h. This was followed by an overnight incubation
at 4°C with the mouse monoclonal antibody (Novartis #677, Sasano et al., 2005) against human
aromatase at 1:3000 dilution in 5% dried semi-skimmed milk/PBST, or a mouse monoclonal
antibody (1:1000 dilution) against human AKR1C3 (17β-HSD5) (Lin et al., 2004), before
incubation (1h) with a donkey anti-mouse IgG conjugated to horseradish peroxidase (Sigma)
at 1:20000 dilution. Proteins were detected by an ECL detection kit (Millipore). To verify the
specificity of the aromatase monoclonal antibody, we used samples of CHO-K1 cells that had
been transiently transfected with human aromatase in a pCMV expression vector (Corbin et
al., 1988) using the GeneJuice® transfection reagent (Novagen Merck Biosciences,
Nottingham, UK) as we have described previously (Kowalewski et al., 2006).
RNA extraction and quantity measurement
Following in vitro treatments, cells were harvested and lyzed in lysis buffer (RLT buffer,
Qiagen, West Sussex, UK) before RNA extraction with the RNeasy mini-kit (Qiagen) per
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manufacturer’s guidance. Exclusion of genomic DNA was achieved with DNase treatment of
samples, on-column, with the RNase free DNase set (Qiagen) according to supplier’s protocol.
Purification and quantification were assessed using a Nanodrop spectrophotometer (ND-1000,
Nanodrop Technologies Inc, Wilmington, DE, USA).
Quantitative measurement of CYP19 and AKR1C3 (17β-HSD5) mRNA
Quantitative Taqman Real-Time PCR was performed to measure relative expression levels of
CYP19 and AKR1C3 mRNA in response to treatments. Briefly, pure RNA (200ng) was
reversed transcribed to cDNA using the RT-Reagent kit (Applied Biosystems, Applera,
Warrington, UK) per supplier’s instructions in a final reaction of 10μl. Then, Real-Time PCR
was performed using commercial Applied Biosystems reagents. Briefly, 2μl cDNA was used
as a template mixed with 1X universal Taqman master cocktail (Applied Biosystems) and the
specific set of 1X primer/probe mixture. Primer/probe sets for all the reported enzyme mRNA
transcripts were purchased and pre-validated (Assay-on-Demand Systems, Applied
Biosystems). A ribosomal 18S primer/probe set was also included and served as an internal
reference control. The CT value obtained for the 18S species was also used to confirm the
quality of the cDNA samples. Mean values reflecting the PCR cycle when the target transcript
started to accumulate relative to 18S (mean dCT in a 40 cycle PCR reaction) are illustrated in
Table 1. Values more than 36 out of 40 PCR cycles were assessed as beyond the limit of robust
detection; however they were included in analysis for comparison reasons. Each reaction was
carried out in duplicate. Samples were evaluated in 96-well plates using an ABI Prism 7900
Sequence Detector (Applied Biosystems).
PCR determination of aromatase promoter usage in H295 cells
Reverse transcription of 2μg of total RNA from 6 h VIP-treated H295 cells was performed
with oligo-dT primers using the Invitrogen SuperscriptTM III reverse transcriptase kit
according to the manufacturer’s instructions. Primer pairs specific for the various alternate-
spliced variants of human aromatase mRNA (Larionov et al., 2003) were used in RT-PCR
reactions to identify which aromatase promoter was being utilized to express aromatase in the
H295 cells. Expression of the coding part of aromatase mRNA was verified examining the
region across the coding aspects of exons II and III as well as the three most common promoter
variants that use the first exon (I.1, I.3, I.4) and the promoter II variant based on our previously
described methodology (Larionov et al. 2003). Primer sets for the PCR are shown in Table 1.
PCR was carried out using Promega PCR master mix with the following cycling conditions;
initial denaturation: 94°C for 2 mins, 35 cycles of 94°C for 30 sec, 58°C for 30 sec, 72°C for
60 sec, final elongation: 72°C for 5 min. PCR products were detected following electrophoresis
in a 2% agarose gel and staining with ethidium bromide.
Immunohistochemistry
Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissue (3 μm
sections) with blocks selected to show tumor and tumor with adjacent normal adrenal tissue.
Sections were deparaffinised in xylene, followed by serial dilutions of ethanol, phosphate-
buffered saline (PBS) and distilled H2O. Microwave permeabilisation was achieved in 0.01 M
sodium citrate buffer pH 6.0 (Sigma, Poole, UK) for 15min followed by cooling to room
temperature for 20 min. After blocking of endogenous peroxidase (3% H2O2 in methanol),
slides were incubated with avidin and biotin (Vector, Peterborough, UK). Sections were then
treated with non-immunized normal goat serum (NGS; Sigma) diluted in PBS (1:5 v/v)
containing 5% (w/v) BSA (Sigma) for 20min at room temperature followed by overnight
incubation at 4°C with a mouse monoclonal antibody against human AKR1C3 (17β-HSD5) at
a 1:1000 dilution (Lin et al., 2004, Vani et al., 2007). Negative controls incubated with
unconjugated mouse IgG1 antibody (Vector) were run routinely at matched concentrations.
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Sections were washed with PBS supplemented with 0.05% Tween 20 (v/v) (PBST; Sigma)
and then incubated with anti-mouse biotinylated IgG1 (1:200 in NGS/PBS/BSA; Vector)
before use of a RTU-ABC elite kit (avidin-biotin complex; HRP conjugated; Vector) for 1h
each. Finally, slides were treated with HRP-conjugated diaminobenzidine (DAB; Vector)
chromagen for 5min, lightly counterstained with hematoxylin and dehydrated in serial ethanol
dilutions (50-100%) and xylene. A similar protocol was employed with the mouse monoclonal
antibody (Novartis #677) against human aromatase diluted 1:1200 in NGS/PBS/BSA at 4°C
(Sasano et al., 2005).
Statistical analysis
Basic statistical analysis was run using the GraphPad Prism 4.00 software (GraphPad Software
Inc., San Diego, USA). Multiple comparisons were performed with one-way ANOVA and
Neuman-Keuls post-hoc tests, whilst single comparisons were achieved with paired Student t-
tests. Statistical significance was considered at p-values ≤ .05 on a minimum of 3 independent
observations.
RESULTS
Expression of aromatase (CYP19) protein in H295 cells treated with either VIP or forskolin
Western immunoblot analysis of H295 cells treated with either VIP (100 nM) or forskolin (10
μM) indicated a marked induction of aromatase protein within 6 h after commencement of
treatment. A representative blot is shown in Figure 1. The identification of a single
immunoreactive species of appropriate molecular size (~55 kDa) in aromatase-transfected
CHO-K1 cells but absence of immunoreactivity in both non-transfected CHO-K1 cells and
untreated H295 cells, confirmed the specificity and sensitivity of the anti-aromatase
monoclonal antibody.
Expression of aromatase (CYP19) mRNA in H295 cells treated with either VIP or forskolin
To determine whether this rapid induction of aromatase protein by the cAMP-PKA pathway
agonists, VIP and forskolin, was transcriptionally or translationally regulated, levels of
aromatase cytochrome P450 mRNA transcripts were measured in the treated H295 cells using
quantitative real-time PCR. As illustrated in Figure 2 both VIP and forskolin treatments
increased the levels of aromatase mRNA 4- and 10-fold respectively within 6 h after
commencement of treatment, indicative that increased aromatase P450 transcription had
occurred, suggesting a transcriptionally-regulated process. On the other hand, inspection of the
raw qRT-PCR data for CYP19 mRNA levels (see Table 2) revealed notable levels of transcripts
even in control H295 cells (mean dCT value of 16). By comparison the dCT value for CYP19
mRNA transcripts in the human NTera2/D1 neuronal cell line that is not recognized as
expressing steroidogenic genes, was 26. The dCT value for aromatase transcripts in the RNA
from the feminizing adrenocortical carcinoma was 16 while they were undetectable in the
aldosterone-producing adrenal adenoma.
Identification of promoter-specific transcripts for CYP19 in H295 cells
As demonstrated in Figure 3, aromatase transcripts associated with utilization of the gonadal-
associated aromatase promoter PII were prominently represented in H295 mRNA prepared
from H295 cells treated with VIP (100 nM) for 6 hours. However, significant amounts of
transcript associated with promoter I.3 were also observed, while there was no evidence for
promoter I.4-associated expression.
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Comparative western immunoblot of aromatase expression in an aldosterone-producing
adrenal adenoma, an estrogen-secreting adrenal carcinoma and H295 cells
Western immunoblot analysis of an aldosterone-producing adrenal adenoma, a feminizing
adrenal carcinoma and H295 cells treated with either VIP (100 nM) or forskolin (10 μM) as
positive controls indicated the presence of CYP19 protein of appropriate molecular size within
the feminizing adrenal carcinoma sample but absence of any immunoreactivity within the
aldosterone-producing adrenal adenoma. The representative blot is shown in Figure 4.
Effect of VIP/forskolin treatment of H295 cells on AKR1C3 (17β-HSD5) protein expression
Western immunoblot analysis of H295 cells treated with either VIP (100 nM) or forskolin (10
μM) revealed the presence in the untreated (Ctrl) cells of a single protein of the expected
molecular size of 37 kDa when probed with mouse monoclonal antibody specific for human
AKR1C3. Furthermore, little if any change in level of the enzyme was found after treatments
with either VIP or forskolin (Fsk) for 6, 12, or 24 hours. A representative blot for a 12 h
treatment period is shown in figure 5.
When AKR1C3 mRNA levels were assessed in H295 cells following treatment with VIP (100
nM) or forskolin (10 μM), no significant differences in mRNA levels were seen between
untreated control (dCT 13.5 ± 0.8, n=3) VIP-treated (dCT 14.2 ± 0.3) or forskolin–treated
(dCT 14.2 ± 0.2) cells (see also Table 2).
A single immunoreactive species of appropriate molecular size (37 kDa) was also identified
in the feminizing adrenal carcinoma and the aldosterone-producing adrenal adenoma (see
figure 5).
Measurement of mRNA transcript levels of CYP11B1, CYP11B2, CYP17, HSD3B1, HSD3B2
in H295 cells, a feminizing adrenal carcinoma and an aldosterone-producing adrenal
adenoma
To provide a comparative analysis of the levels of mRNA transcripts of various relevant
adrenocortical enzymes besides AKR1C3 and CYP19, we used quantitative real-time PCR
with validated primer/probe sets for transcripts of the genes listed in Table 2. The data are
provided in Table 2 as dCT values for each transcript, the cycle number CT to achieve the
threshold fluorescence level for the gene of interest minus the CT value for the 18S
housekeeping transcript.
Immunolocalization of AKR1C3 (17β-HSD5) and CYP19 (aromatase) expression
Immunolocalization of AKR1C3 (17β-HSD5) and CYP19 (aromatase) in a feminizing adrenal
cortical carcinoma and adjacent normal adrenocortical tissue are illustrated in Figure 6. Both
localized to cytoplasm of cells. 17β-HSD5 protein was immunolocalized not only in the
carcinoma cells but also principally in the lipid-poor adrenal zona reticularis with much less
intense staining observed in the lipid-rich zona fasciculata. The localization of CYP19 was
restricted to the carcinoma.
DISCUSSION
In these current studies we have demonstrated the expression of both aromatase cytochrome
P450 (CYP19) and AKR1C3 (type 5 17β-hydroxysteroid dehydrogenase) in H295 cells at the
level of mRNA transcript and protein. CYP19 mRNA has been previously demonstrated in
H295 cells (Staels et al., 1993; Watanabe and Nakijin, 2004; Watanabe et al., 2006) and the
presence of translated protein has been assumed based on the detection of aromatase activity
using the tritiated water technique. However, while AKR1C3 appeared constitutively
expressed, aromatase protein was only observed after treatment with the cAMP-PKA pathway
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agonists, VIP and forskolin. Because AKR1C3 is a reductive NADPH-dependent 17-
ketosteroid reductase capable of in vivo conversion of androstenedione to testosterone and
estrone to estradiol (reviewed in Penning and Drury, 2007), our finding is indicative that H295
cells can biosynthesize the active estrogen, estradiol, directly from cholesterol.
Notwithstanding the evidence that cAMP-PKA pathway agonists, namely VIP and forskolin,
increased the level of CYP19 mRNA transcripts in H295 cells suggesting an element of
transcriptional control of CYP19 expression, our findings are also strongly suggestive of
notable translational control of CYP19 expression. This conclusion is based on the
demonstration of a quite rapid accumulation of CYP19 protein within 6 hours after
commencement of treatment along with significant levels of CYP19 mRNA transcripts even
in untreated H295 cells (see Table 2). One explanation from a number of plausible ones could
be that a microRNA is active in the untreated cells.
The aromatase enzyme is the single product of the human CYP19 gene. Multiple signaling
pathways regulate CYP19 expression in the various tissues where aromatase is found. The end
response to the multiplicity of signals is under the control of multiple promoters utilizing
alternative splicing of different upstream exons with exon II containing the start site of
translation (reviewed in Bulun et al., 2005). In the current study using H295 cells after
stimulation of the cAMP/PKA pathway with VIP we found that the principal aromatase
promoters utilized were promoters PII and I.3. The proximal regions of both of these promoters
contain cAMP response element (CRE)-like sequences which may be activated in a cAMP-
dependent manner by VIP acting through the VPAC1 receptor. Indeed it have previously shown
that forskolin most likely activates aromatase expression in H295 cells via these promoters
(Watanabe and Nakajin, 2004).
It was of interest to compare data obtained from the study of H295 cells with the situation
existing in two different examples of human adrenocortical tumors, a feminizing adrenocortical
carcinoma and an aldosterone-producing adrenal adenoma. Western immunoblotting of these
tumors revealed that the feminizing adrenal carcinoma expressed notable amounts of both
CYP19 and AKR1C3 consistent with clinical evidence that it was secreting bioactive estrogens.
However, the aldosterone-producing adrenal adenoma did not express aromatase enzyme and
the level of AKR1C3 was reduced compared to that found in the feminizing adrenal tumor.
The level of CYP19 mRNA transcripts relative to 18S housekeeping gene transcripts in the
feminizing adrenal tumor were similar to those observed in the H295 cells (see Table 2),
suggestive that H295 cells are an appropriate model for in-depth studies of mechanisms
underlying development of such tumors.
Another candidate 17-ketosteroid reductase that is effective in converting in vivo estrone to
estradiol is the type 1 17β-hydroxysteroid dehydrogenase. However, we were unable to detect
the expression of this enzyme on immunoblotting of H295 cells or the tumors using a rabbit
polyclonal antibody raised against the human placental enzyme (data not shown).
Analysis of the mRNA transcript levels of other key steroidogenic enzymes in these two tumors
demonstrated much higher levels of CYP11B2 (aldosterone synthase) transcripts in the
aldosterone-producing adenoma versus the feminizing adrenal tumor (see Table 2). This could
be predicted since it has recently been documented that 100% of aldosterone-producing adrenal
adenomas have highly elevated CYP11B2 transcript levels compared to normal adrenals (Ye
et al., 2007). The observation that CYP17 mRNA levels in the aldosterone-producing adenoma
were similar to those in the estrogen-producing adrenal carcinoma is suggestive that the 17-
hydroxysteroids, e.g., cortisol, were produced in the adenoma and thereby acting as a brake on
the production of aldosterone, a 17-deoxysteroid. In both tumors as well as H295 cells, the
predominant HSD3B gene expressed was the gonadal/adrenal-specific HSD3B2. Transcripts
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of the HSD3B1 gene were readily detectable, albeit at a lower level (<10%) than HSD3B2. It
was observed, however, that forskolin treatment of H295 cells also increased HSD3B1
transcript levels suggestive that this isoform may be expressed at a low level in the human
adrenal cortical pathophysiologies and might be responsible for the very low but nevertheless
detectable plasma levels of cortisol found in individuals with 3β-hydroxysteroid
dehydrogenase deficiency congenital adrenal hyperplasia due to a totally non-functional
HSD3B2 gene product.
Finally we demonstrated by immunohistochemistry the presence of both AKR1C3 (17β-
hydroxysteroid dehydrogenase type 5) and CYP19 in the feminizing adrenal carcinoma. While
CYP19 was not present in the adjacent normal adrenocortical tissue, AKR1C3 was localized
predominantly in the lipid-poor region of the human adrenal zona reticularis. This finding is
supportive of the notion that the zona reticularis, the principal site of adrenal C19-steroid
production, is potentially capable of synthesising the active androgen testosterone. The
capacity to produce testosterone in this compartment may be favoured under conditions of
stress when androstenedione production is facilitated because of increased 3β-hydroxysteroid
dehydrogenase activity.
In summary, we have presented in these studies further evidence that H295 cells maintain the
enzymology to produce directly the potent estrogen, estradiol, consolidating evidence that they
be considered as a suitable model system to explore the mechanisms underlying feminizing
adrenal cortical carcinomas.
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Figure 1.
Representative western immunoblot of aromatase (CYP19) protein in H295 cells after
treatment (6 h) with VIP (100 nM) or forskolin (10 μM). Lane 1: CHO-K1 cells transfected
with human CYP19 cDNA (25 μg protein); lane 2: non-transfected CHO-K1 cells (25 μg
protein); lane 3: untreated (Ctrl) H295 cells (25 μg protein); lane 4: VIP-treated H95 cells (25
μg protein); lane 5: Forskolin (Fsk)-treated H295 cells (25 μg protein).
Nicol et al. Page 10
Mol Cell Endocrinol. Author manuscript; available in PMC 2010 March 5.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2.
The effects of VIP and forskolin (Fsk) on CYP19 (aromatase) mRNA levels in H295 cells.
H295 cells were treated with either VIP (100 nM) or forskolin (10 μM) for 6 h. RNA was
isolated and mRNA levels analyzed by quantitative real-time PCR as described in Materials
and Methods (*p<0.05 versus control).
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Figure 3.
PCR amplification of aromatase (CYP19) transcripts in human H295 adrenocortical cells. After
reverse transcription cDNA samples were amplified using primers specific for the various
CYP19 gene transcripts. M=size markers, size of fragments is shown in bp; CR=coding region
(exons II-III); PII=promoter II-specific region; I.1=promoter I.I; I.3=promoter I.3 and I.
4=promoter I.4. The negative (Neg) lane is a PCR control.
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Figure 4.
Western immunoblot of aromatase (CYP19) protein in an aldosterone-producing adrenal
adenoma, a feminizing estrogen-secreting adrenal carcinoma and H295 cells after treatment
(12 h) with VIP (100 nM) or forskolin (10 μM). Lane 1: Aldosterone-producing adrenal
adenoma (15 μg protein); lane 2: Estrogen-secreting adrenal carcinoma (15 μg protein); lane
3: Untreated control H295 cells (15 μg protein); lane 4: Forskolin (Fsk)-treated H95 cells (15
μg protein); lane 5: VIP-treated H295 cells (15 μg protein).
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Figure 5.
Western immunoblot of AKR1C3 (17β-HSD5) protein in a feminizing estrogen-secreting
adrenal carcinoma, an aldosterone-producing adrenal adenoma, and H295 cells after treatment
(24 hours) with either VIP (100 nM) or forskolin (10 μM). Lane 1: Aldosterone-producing
adrenal adenoma (25 μg protein); lane 2: Estrogen-secreting adrenal carcinoma (25 μg protein);
lane 3: Untreated control H295 cells (25 μg protein); lane 4: Forskolin (Fsk)-treated H295 cells
(25 μg protein); lane 5: VIP-treated H295 cells (25 μg protein).
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Figure 6.
Immunolocalization of AKR1C3 and CYP19 in an adrenal containing an estrogen-secreting
adrenal adenocarcinoma. A. Immunohistochemistry for AKR1C3 showing normal adrenal
cortex with higher expression centrally in the lipid-poorer cells of the zona reticularis (ZR)
than in the lipid-rich cells of the zona fasciculata (ZF); the adrenal capsule is located at the
extreme right of the image (original magnification x20). B. Immunohistochemistry for
AKR1C3 showing normal adrenal cortex with higher expression in the lipid-poorer cells of
the zona reticularis (centre) than in the lipid-rich cells of the zona fasciculata (right); adrenal
capsule to the far right of the image (original magnification x40). C. Immunohistochemistry
for AKR1C3 showing expression in the carcinoma cells (left), tumor capsule (centrally) and
some of the normal adrenocortical cells (right) (original magnification x20). D.
Immunohistochemistry for aromatase, showing expression in many of the carcinoma cells (left)
and the normal adrenal cortex to be negative (right) (original magnification x20).
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Table 1
PCR primer sets for the determination of aromatase promoter usage
Sense Antisense
Exon II-III coding region GACTCTAAATTGCCCCCTCTG CAGAGATCCAGACTCGCAATG
Exon I.1-specific CTGGAGGGCTGAACACGTGG CAGAGATCCAGACTCGCAATG
Exon I.3-specific CCTTGTTTTGACTTGTAACCA CAGAGATCCAGACTCGCAATG
Exon I.4-specific GACCAACTGGAGCCTGACAG CAGAGATCCAGACTCGCAATG
Promoter II-specific AACAGGAGCTATAGATGAAC CAGAGATCCAGACTCGCAATG
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